Fluzoparib trials for Breast cancer

All Fluzoparib trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Fluzoparib for Breast cancer

• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
  NCT05891093 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 15 locations
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
  NCT05761470 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
  NCT05759546 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
  NCT06255392 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study Fluzoparib for Breast cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.